TREATMENT ELIGIBILITY

TREATMENT ELIGIBILITY

ARE YOUR PATIENTS ELIGIBLE FOR
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)?

Enter your patient's mutations below to see if they are eligible for TRIKAFTA.
You may determine eligibility for up to 5 patients at once.

Enter your patient’s mutations below to see if they are eligible for TRIKAFTA.

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

Mutation 1
Mutation 2 (optional)
1.

Mutation(s) not recognized. Please check to see if they were entered correctly.

Mutation(s) not recognized. Please check to see if they were entered correctly.

Learn how to enter 2 or more mutations

Please see most common responsive mutations below.

Most Common Responsive Mutations1,2

Indicated based on clinical data
F508del

or

Other indicated mutations based on in vitro data1,2,a

G551D | R117H | D1152H | G85E
L206W | R347P | A455E

170 less common mutations are also eligible.

Most Common Responsive Mutations1,2

Indicated based on clinical data
F508del

or

Other indicated mutations based on in vitro data1,2,a

G551D  |  R117H  |  D1152H  |  G85E
L206W  |  R347P  |  A455E

170 less common mutations are also eligible.

Mutations were considered responsive if net chloride transport increased by ≥10% of normal over baseline after adding elexacaftor/tezacaftor/ivacaftor.

 

aThese mutations are present in ≥0.6% of individuals with CF.2